Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: small molecule therapeutics - Quimatryx

Next Previous
Search
Drug Profile

Research programme: small molecule therapeutics - Quimatryx

Alternative Names: DNA methyltransferase inhibitors - Quimatryx; DNMT inhibitors - Quimatryx; HDAC inhibitors - Quimatryx; HDAC2 selective inhibitor - Quimatryx; HDAC6 selective inhibitor - Quimatryx; Isoform selective HDAC inhibitor - Quimatryx; JMJ inhibitors - Quimatryx; JMJ2DC(GASC1) inhibitors - Quimatryx; LFA-1 integrin inhibitor - Quimatryx; Lymphocyte function-associated antigen-1 inhibitor - Quimatryx; Proteasome inhibitors - Quimatryx; QTX 100; QTX 125; QTX 153; QTX 200; QTX 300; QTX 400; Sirtuin inhibitors and activators - Quimatryx

Latest Information Update: 28 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IkerChem
  • Developer Quimatryx
  • Class Antidementias; Antineoplastics; Neuroprotectants; Small molecules
  • Mechanism of Action HDAC6 protein inhibitors; Lymphocyte function-associated antigen-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Mantle-cell lymphoma; Multiple sclerosis
  • Discontinued Liver metastases

Most Recent Events

  • 28 Apr 2022 No recent reports of development identified for preclinical development in Mantle-cell-lymphoma in Spain (PO)
  • 28 Apr 2022 No recent reports of development identified for preclinical development in Multiple-sclerosis in Spain (PO)
  • 28 Aug 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in Spain (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top